DDInter737 DDInter1376
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Fingolimod {u} (Compound) treats {v} (Disease) multiple sclerosis
Fingolimod {u} (Compound) binds {v} (Gene) S1PR4
Fingolimod {u} (Compound) is included by {v} (Pharmacologic Class) Sphingosine 1-Phosphate Receptor Modulators
Fingolimod {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Fingolimod {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olanzapine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Fingolimod (Compound) treats multiple sclerosis (Disease)
Fingolimod (Compound) binds S1PR4 (Gene)
Fingolimod (Compound) is included by Sphingosine 1-Phosphate Receptor Modulators (Pharmacologic Class)
Fingolimod (Compound) causes Cardiac arrest (Side Effect)
Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine
Fingolimod may lead to a major life threatening interaction when taken with Tizanidine
Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib